JP2011519868A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519868A5
JP2011519868A5 JP2011507707A JP2011507707A JP2011519868A5 JP 2011519868 A5 JP2011519868 A5 JP 2011519868A5 JP 2011507707 A JP2011507707 A JP 2011507707A JP 2011507707 A JP2011507707 A JP 2011507707A JP 2011519868 A5 JP2011519868 A5 JP 2011519868A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
inhibitor
drug
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011507707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/042657 external-priority patent/WO2009137378A2/en
Publication of JP2011519868A publication Critical patent/JP2011519868A/ja
Publication of JP2011519868A5 publication Critical patent/JP2011519868A5/ja
Withdrawn legal-status Critical Current

Links

JP2011507707A 2008-05-05 2009-05-04 癌を処置するための化学療法剤の連続投与 Withdrawn JP2011519868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5040508P 2008-05-05 2008-05-05
US61/050,405 2008-05-05
PCT/US2009/042657 WO2009137378A2 (en) 2008-05-05 2009-05-04 Sequential administration of chemotherapeutic agents for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2011519868A JP2011519868A (ja) 2011-07-14
JP2011519868A5 true JP2011519868A5 (https=) 2012-06-07

Family

ID=40940448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507707A Withdrawn JP2011519868A (ja) 2008-05-05 2009-05-04 癌を処置するための化学療法剤の連続投与

Country Status (6)

Country Link
US (1) US20110129456A1 (https=)
EP (1) EP2282739A2 (https=)
JP (1) JP2011519868A (https=)
CA (1) CA2722992A1 (https=)
MX (1) MX2010012064A (https=)
WO (1) WO2009137378A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ
WO2008083288A2 (en) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals Purifiction of romidepsin
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2718918A1 (en) * 2008-03-25 2009-11-26 Schering Corporation Methods for treating or preventing colorectal cancer
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
NZ592151A (en) 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
AU2011223883B2 (en) 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
EP2640390A4 (en) * 2010-11-17 2014-08-06 Glaxosmithkline Ip No 2 Ltd METHODS OF TREATING CANCER
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CA2827673C (en) * 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 組合せ
MX373150B (es) * 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
US10555931B2 (en) 2014-05-28 2020-02-11 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
CN106999734B (zh) * 2014-09-29 2020-06-16 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法
PT3212670T (pt) 2014-10-29 2021-02-15 Bristol Myers Squibb Co Terapêutica de combinação para cancro
KR102309882B1 (ko) * 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
WO2017075363A1 (en) * 2015-10-30 2017-05-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
AU2016349279A1 (en) * 2015-11-03 2018-05-10 Board Of Regents, The University Of Texas System Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
SMT202100573T1 (it) 2016-12-22 2021-11-12 Calithera Biosciences Inc Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi
WO2018217669A1 (en) * 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
SG11202001606XA (en) 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor

Similar Documents

Publication Publication Date Title
JP2011519868A5 (https=)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
JP2011515478A5 (https=)
JP2019503674A5 (https=)
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
JP2012247438A5 (https=)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
US20110129456A1 (en) Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
US10544222B2 (en) PD1/CTLA4 binders
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
US9388239B2 (en) Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CA2718918A1 (en) Methods for treating or preventing colorectal cancer
TW201726741A (zh) Ctla4結合劑
JP2014516964A5 (https=)
JP2014516964A (ja) 治療用抗igf1r合剤
JP2017538673A5 (https=)
NZ561648A (en) Methods and composition of IGF1R inhibitors for treating or preventing cancer
JPWO2021055705A5 (https=)